Latest Headlines

1. Werum IT Solutions Launches New Smart Biometric Authentication Solution K.ME-IN For Pharma And Biotech In Cooperation With Nymi 1/9/2020

   Werum IT Solutions is excited to announce the launch of K.ME-IN, a biometric authentication solution with Nymi for Werum’s PAS-X Manufacturing Execution System (MES). The new solution will allow users on the pharmaceutical or biopharmaceutical shop floor to securely and seamlessly authenticate to systems, devices and machines via a smart wristband. In the future, K.ME-IN will be extended to allow user authentication via further biometric means such as iris scan, face recognition, fingerprint or a combination of those.

2. Tessa Therapeutics Announces Plans To Open New Cell Therapy Manufacturing Facility In Singapore In Late 2020 12/19/2019

   Tessa Therapeutics (Tessa), a clinical-stage cell therapy company focused on the development of innovative cell therapies to treat cancer, today announced plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in Singapore by end-2020, which will be one of the leading commercial-scale cell therapy manufacturing facilities in Asia.

3. RoosterBio Expands Maryland Facility For Regenerative Medicine Needs 12/19/2019

   RoosterBio Inc., a cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, expanded its facility in Frederick, Maryland.

4. GE Healthcare Life Sciences Allies With Pharmadule Morimatsu To Expand KUBio 12/5/2019

   The KUBio “factory in a box” is expanding to accelerate the accessibility of biotherapeutics on a global scale. Additional modular platforms will be introduced in 2020 allowing biopharma manufacturers to quickly scale up vaccines, viral vector-based therapies, and other novel modalities.

5. Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts 12/5/2019

   New facility will create 200 new jobs and accelerate commercialization of gene and cell therapies.

6. VGXI Selects BE&K As Design Firm For New 240,000 Square Foot Manufacturing Facility 12/3/2019

   VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services company BE&K Building Group as Design-Build Partner for the initial phase of its new manufacturing site.

7. Astellas Buys Audentes Therapeutics For $3B For Gene Therapy Drug Manufacturing Expansion 12/2/2019

   Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. (Chairman and CEO: Matthew R. Patterson, “Audentes”), today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3B.

8. Speeding Cell, Gene Therapy Development 11/25/2019

   An innovative new major private-public partnership led by Harvard and MIT aims to accelerate one of the hottest and most promising areas of medical research: cell and gene therapy

9. Premier Research Renews Sponsorship For World Orphan Drug Congress Europe 11/8/2019

   Premier Research is proud to once again be a sponsor of the World Orphan Drug Congress (WODC) Europe taking place November 12-14, 2019, in Barcelona, Spain. As part of our ongoing support for this innovative conference, Jonathan Kornstein, Executive Director, Program Strategy, Rare Disease & Pediatrics, will present a session entitled "A Partnership That Lasts: Key Considerations When Working With CROs on Rare Disease Studies."

10. IPS Announces New Office In Cherry Hill, NJ For Pharma, Cell / Gene / Bio Clients 11/7/2019

    IPS-Integrated Project Services, LLC, a leading provider of Engineering, Procurement, Construction Management and Commissioning, Qualification, and Validation (EPCM/CQV) services, announces the continued expansion in the Americas region with the opening of a new office located in Cherry Hill, New Jersey.